Share this article
Share this article
WASHINGTON, April 2, 2021 /PRNewswire/ The National Pharmaceutical Council (NPC), a health policy research organization dedicated to the advancement of evidence, science and medical innovation, today announced the appointment of veteran drug pricing and health policy expert John M. O Brien, Pharm.D., MPH, as president and chief executive officer.
O Brien, who will assume the role on June 1, will be responsible for overseeing NPC s policy research and communications capacity, partnerships with other health care organizations, and strategic vision.
The National Pharmaceutical Council (NPC), a health policy research organization dedicated to the advancement of evidence, science and medical innovation, announced the appointment of veteran drug pricing and health policy expert John M. O’Brien, Pharm.D., MPH, as president and chief executive officer.
POLITICO
Sign up for POLITICO Playbook today.
Email
Sign Up
By signing up you agree to receive email newsletters or updates from POLITICO and you agree to our privacy policy and terms of service. You can unsubscribe at any time and you can contact us here. This sign-up form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Presented by Facebook
John Boehner’s new book includes a rollicking romp through the GOP in the years just before Donald Trump. | Alex Wong/Getty Images
DRIVING THE DAY
JOHN BOEHNER’S scorching new book,
“ON THE HOUSE,” which will be out April 13 from St. Martin’s Press.
If you re having trouble paying for your medications, Drug Company X may be able to help.
You may have heard sentences like this at the end of pharmaceutical ads on television, and some clinicians may wonder what exactly the companies do to help their patients. The help usually comes in the form of what drugmakers call a copay coupon or copay assistance card for, say, $50 that the patient can present at the pharmacy counter to lower the amount they have to pay for their prescription.
Insurers are notified when their patients use copay coupons, and many of them use the data to compile copay accumulator records for enrollees. Often, insurers won t allow the money paid by drugmakers to count toward the patient s deductible or out-of-pocket costs.